Pharma

OpenAI Wants to “Accelerate” the Work Behind New Drugs

01

OpenAI acquires Orchestra Bio to enhance drug development coordination software.

02

New software aims to connect research, budgets, and execution in pharmaceutical companies.

03

OpenAI plans to integrate Orchestra's technology into its existing life sciences models.

04

Acquisition addresses fragmented systems that complicate drug research and manufacturing timelines.

05

Financial details of the acquisition remain undisclosed.